Is DOPA a neurotransmitter?
Y Misu, Y Goshima, T Miyamae - Trends in Pharmacological Sciences, 2002 - cell.com
Abstract Historically, 3, 4-dihydroxyphenylalanine (DOPA) has been considered to be an
inert amino acid that alleviates the symptoms of Parkinson's disease by its conversion to …
inert amino acid that alleviates the symptoms of Parkinson's disease by its conversion to …
L-3, 4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system
Y Misu, K Kitahama, Y Goshima - Pharmacology & therapeutics, 2003 - Elsevier
Historically, 3, 4-dihydroxyphenylalanine (DOPA) has been believed to be an inert amino
acid that alleviates the symptoms of Parkinson's disease by its conversion to dopamine via …
acid that alleviates the symptoms of Parkinson's disease by its conversion to dopamine via …
Expression of ocular albinism 1 (OA1), 3, 4-dihydroxy-L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs
N Fukuda, S Naito, D Masukawa, M Kaneda… - Brain Research, 2015 - Elsevier
Oa1 is the casual gene for ocular albinism-1 in humans. The gene product OA1, alternatively
designated as GPR143, belongs to G-protein coupled receptors. It has been reported that …
designated as GPR143, belongs to G-protein coupled receptors. It has been reported that …
The Cardiovascular Actions of DOPA Mediated by the Gene Product of ocular albinism 1
Y Goshima, F Nakamura, D Masukawa, S Chen… - Journal of …, 2014 - Elsevier
Abstract l-3, 4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and
the single most effective agent in the treatment of Parkinson's disease. One problem with …
the single most effective agent in the treatment of Parkinson's disease. One problem with …
Localization of ocular albinism-1 gene product GPR143 in the rat central nervous system
D Masukawa, F Nakamura, M Koga, M Kamiya… - Neuroscience …, 2014 - Elsevier
Abstract l-3, 4-Dihydroxyphenylalanine (DOPA) has been believed to be a precursor of
dopamine, and itself being an inert amino acid. Previously, we have proposed DOPA as a …
dopamine, and itself being an inert amino acid. Previously, we have proposed DOPA as a …
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors
V Pendolino, V Bagetta, V Ghiglieri, C Sgobio… - Experimental …, 2014 - Elsevier
Parkinson's disease (PD) patients exhibit motor and non-motor symptoms that severely
affect quality of life. Cognitive alterations in PD subjects have been related to both structural …
affect quality of life. Cognitive alterations in PD subjects have been related to both structural …
Augmentation of Serotonin‐Induced Inhibition of Neuronal Activity in the Hippocampus Following Repeated Treatment with Methamphetamine
T Kimura, K Ishihara, K Ozawa… - Annals of the New York …, 2004 - Wiley Online Library
Electrophysiological studies were performed to determine whether or not hippocampal
serotonergic modulation was affected following repeated administration of …
serotonergic modulation was affected following repeated administration of …
DOPA cyclohexyl ester potently inhibits aglycemia-induced release of glutamate in rat striatal slices
M Hashimoto, T Miyamae, I Yamamoto… - Neuroscience research, 2003 - Elsevier
Brain ischemic insult causes glutamate release and resultant neuronal cell death. We here
show that l-3, 4-dihydroxyphenylalanine (DOPA) is a positive regulatory factor for glutamate …
show that l-3, 4-dihydroxyphenylalanine (DOPA) is a positive regulatory factor for glutamate …
In vivo antagonism of the behavioral responses to L-3-, 4-dihydroxyphenylalanine by L-3-, 4-dihydroxyphenylalanine cyclohexyl ester in conscious rats
N Matsushita, Y Misu, Y Goshima - European journal of pharmacology, 2009 - Elsevier
To establish the neurotransmitter role (s) of L-3, 4-dihydroxyphenylalanine (DOPA) in its own
right, we attempted to clarify whether ip injection of a DOPA antagonist, DOPA cyclohexyl …
right, we attempted to clarify whether ip injection of a DOPA antagonist, DOPA cyclohexyl …
15 Behavioral Effects of Exogenously Applied and Endogenously Released DOPA
Y Misu, K Honjo, Y Goshima - Neurobiology of DOPA as a …, 2005 - books.google.com
Since the 1950s [1, 2], exogenously applied L-3, 4-dihydroxyphenylalanine (levodopa) has
been generally thought to be an inert amino acid that alleviates the symptoms of Parkinson's …
been generally thought to be an inert amino acid that alleviates the symptoms of Parkinson's …